Skip to main content
. Author manuscript; available in PMC: 2008 Dec 29.
Published in final edited form as: Toxicol Appl Pharmacol. 2007 Aug 7;225(2):206–213. doi: 10.1016/j.taap.2007.07.016

Fig. 1. UROtsa-725 had reduced endogenous Nrf2.

Fig. 1

(A) UROtsa-725 and its negative control URotsa-724 were derived from URotsa cells stably infected with Nrf2-siRNA or scrambled-siRNA using retrovirus-based vectors. Equal amounts of total lysates were subjected to immunoblot analysis with anti-Nrf2 and anti-tubulin antibodies. (B) The mRNA levels of Nrf2, Keap1, NQO1, and HO-1 in UROtsa-724 and UROtsa-725 were compared by real-time RT-PCR. (C) NQO1 activities in the lysates of UROtsa-724 and UROtsa-725 were measured using DCPIP as a substrate. (D) Intracellular glutathione concentrations in UROtsa-724 and UROtsa-725 were measured using the QuantiChrom glutathione assay kit. (E) UROtsa-724 and UROtsa-725 cell lines were either left untreated or treated with 20 μM As(III) for 16 h. Following incubation of cells with DCF, ROS was detected using flow cytometry. The bar graph represents the means of fluorescence values.